Three people have died after contracting the Marburg virus, and three more are suspected of being linked to the extremely contagious haemorrhagic sickness, Ethiopia's health ministry announced on Monday. Ethiopia's Health Minister, Mekdes Daba, said the government, which announced a Marburg epidemic on Friday, had tested 17 probable cases in the country's south. The outbreak has been recorded in the Omo region.

Recent research has revealed that pregnancy and breastfeeding generate long-lasting CD8+ T lymphocytes that remain active in breast tissue, offering enduring immune protection. This groundbreaking discovery, described by scientists as a "paradigm shift," was unveiled at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting in Berlin and published simultaneaously in Nature. The findings have the potential to reshap how sceintistws and clinicians understand breast cancer (BC) prevention and treatment, especially regarding immune-related mechanisms in women's health.

The World Health Organization (WHO) has officially recommended the use of Ienacapavir, a long-acting injectable drug, for HIV prevention. This milestone announcement was made on July 14 during the 13th International AIDS Society Conference in Kigali. The recommendation aims to help countries adopt lenacapavir, especially in high-burden areas and among vulnerable populations. Lenacapavir, marketed as Sunlenca for treatment and Yeztugo for prevention, is a capsid inhibitor approved in 2022 for certain HIV treatments. Its unique mechanism blocks HIV replication by targeting the virus's protective protein shell. Unlike daily oral pills, lenacapavir is administered only twice a year via injection and has shown near-complete protection in clinical trials.

A recent study has revealed that metabolic health indicators, particularly even slight elevations in blood sugar, play a central role in altering the reproductive and sexual functions of aging men. The findings were unveiled during the 2025 annual meeting of the Endocrine Society (ENDO), held from July 12 to 15 at the Moscone Convention Center in San Francisco, California, USA.

A new study published in BJS by Oxford University Press has revealed a sharp global rise in early-onset gastrointestinal (GI) cancers, particularly among people under age 50. While overall colorectal cancer rates have declined in countries like the United States, early-onset cases, especially among those born after 1990, have surged significantly. In fact, people born in 1990 face twice the risk of developing colon cancer and four times the risk of rectal cancer compared to those born in 1950.